Biological Information
Background Information:
Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Essential component of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. With MAP2K4/MKK4, is the one of the only known kinase to directly activate the stress-activated protein kinase/c-Jun N-terminal kinases MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 and MAP2K7/MKK7 both activate the JNKs by phosphorylation, but they differ in their preference for the phosphorylation site in the Thr-Pro-Tyr motif. MAP2K4/MKK4 shows preference for phosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thr residue. The monophosphorylation of JNKs on the Thr residue is sufficient to increase JNK activity indicating that MAP2K7/MKK7 is important to trigger JNK activity, while the additional phosphorylation of the Tyr residue by MAP2K4/MKK4 ensures optimal JNK activation. Has a specific role in JNK signal transduction pathway activated by pro-inflammatory cytokines. The MKK/JNK signaling pathway is also involved in mitochondrial death signaling pathway, including the release cytochrome c, leading to apoptosis. Part of a non-canonical MAPK signaling pathway, composed of the upstream MAP3K12 kinase and downstream MAP kinases MAPK1/ERK2 and MAPK3/ERK1, that enhances the AP-1-mediated transcription of APP in response to APOE.
Family:
Kinase
Sub Family:
STE
Class:
Protein Ser/Thr
Protein Name:
MAPKK 7
Uniprot Number:
O14733
Protein Aliases:
JNK-activating kinase 2; MAPK/ERK kinase 7 (MEK 7); Stress-activated protein kinase kinase 4 (SAPK kinase 4; SAPKK-4; SAPKK4);c-Jun N-terminal kinase kinase 2 (JNK kinase 2; JNKK 2)
Gene Name:
MAP2K7
Gene ID:
5609
Gene Aliases:
JNKK2, MEK7, MKK7, PRKMK7, SKK4
Accession Number:
NM_145185.4
Organism:
Human
Assay Information
Assay Type:
Biochemical
Assay Sub Type:
Enzymatic
Functional Mode:
Antagonist
Detection Method:
Luminescence
Measured Response:
Luminescence
Testing Information
Tracer:
ADP
ATP Concentration:
15 µM
Incubation:
40 min at RT
Test Sample Requirements:
Minimum for 1) Screen: 60 µl of 10 mM stock -OR- 1 mg (pre-weighed) for 10µM final testing. 2) Dose Response: 90 µl of 10 mM stock -OR- 1 mg (pre-weighed) for a top concentration at 10 µM.
Minimum Order Quantity:
10
Turnaround Time
Standard:
15 Business Days
Reference Compound Data
Clinical Relevance
Therapeutic Area:
Oncology/Immuno-Oncology
Additional Information
Brand:
SafetyScreen
Testing Location:
France - Celle L'Evescault
RELATED SOLUTIONS